Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

AERIUS D-12 MODIFIED RELEASE TABLETS 2.5MG/120MG [SIN13772P]

Active ingredients: (IR LAYER) DESLORATADINE, MICRONIZED | (SR LAYER) PSEUDOEPHEDRINE SULFATE

View product's general information
Last updated on 9 October 2026

Product Info

AERIUS D-12 MODIFIED RELEASE TABLETS 2.5MG/120MG

[SIN13772P]

Product information

Active Ingredient and Strength

(IR LAYER) DESLORATADINE, MICRONIZED - 2.5 MG
(SR LAYER) PSEUDOEPHEDRINE SULFATE - 120 MG

Dosage Form

TABLET, DELAYED RELEASE

Manufacturer and Country

PATHEON INC., WHITBY OPERATIONS - CANADA

Registration Number

SIN13772P

Licence Holder

ORGANON SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

R01BA52

Prescription-only Medicines with Exemptions for Supply without Prescription

As a modified release oral solid dosage form containing desloratadine 2.5mg and pseudoephedrine 120mg

  • Indications: For the relief of symptoms associated with allergic rhinitis including nasal congestion, sneezing, runny nose, itching of the nose and/or eyes

  • It should be administered when both the antihistaminic properties of desloratadine and the decongestant effect of pseudoephedrine are required.

  • Dosing regimen: 1 tablet twice daily

  • Maximum daily dose: 2 tablets

  • Maximum supply: 10 tablets

  • Minimum age: 12 years

Indication

INDICATIONS AND USAGE: AERIUS D-12 Tablets are indicated for the relief of the nasal and non-nasal symptoms of allergic rhinitis, including nasal congestion, in adults and children 12 years of age and older.

AERIUS D-12 Tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant activity of pseudoephedrine are desired.

Dosing

DOSAGE AND ADMINISTRATION: Adults and adolescents (≥ 12 years of age): One AERIUS D-12 Tablet twice a day regardless of mealtime. For oral use.

Caution: Do not chew, break or crush the tablet. Swallow whole.

The duration of treatment should be kept as short as possible and should not be continued after the symptoms have disappeared. The incremental efficacy of pseudoephedrine over desloratadine alone has not been studied beyond a duration of two weeks.

Contraindications

CONTRAINDICATIONS: AERIUS D-12 Tablets are contraindicated in patients who are hypersensitive to the active substance, to any of its excipients, to adrenergic agents or to loratadine.

As AERIUS D-12 contains pseudoephedrine, it is also contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment.

AERIUS D-12 is also contraindicated in patients with

  • narrow-angle glaucoma,

  • urinary retention,

  • severe hypertension,

  • severe coronary artery disease,

  • hyperthyroidism,

  • a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke. This is due to the alpha-mimetic activity of pseudoephedrine in combination with other vasoconstrictors such as bromocriptine, pergolide, lisuride, cabergoline, ergotamine, dihydroergotamine or any other decongestant medicinal product used as a nasal decongestant, either by oral route or by nasal route (phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline...).